NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune ...

NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune ...

A Phase I clinical trial, whose results have been published in the prestigious journal Blood, reveals that this new CAR-T30 therapy promotes the expansion of memory T cells, leading to long ...

Apr. 29, 2025 — A Phase I trial involving ten patients with relapsed or refractory classical Hodgkin lymphoma or T-cell lymphoma has achieved a 100% overall response rate and a 50% complete ...

Amgen today announced financial results for the first quarter of 2025. "Demand for our products was strong globally in the first quarter. Ongoing new product launches and successful Phase 3 trial ...

In a deal that could top $1 billion, Merck & Co has teamed up with US biotech Janux Therapeutics to bring T-cell immunotherapies to cancer patients. The agreement sees San Diego-based Janux in ...

This review explores the role of PET in imaging immune activation, particularly in oncology. 18F-FDG is widely used for assessing treatment response to immunotherapies and can demonstrate unique ...

AT&T Wireless is the cellular branch of AT&T services. The company offers a variety of plan options to suit every customer's needs. Choices include unlimited text, talk and data plans, shared data ...